Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis.

ABSTRACT:

Purpose

Recent works have characterized that metastatic site can affect the tumour immune profiles and efficiency of cancer immunotherapies. The prognosis of HER2-positive breast cancer is associated with the characteristics of the tumour immune microenvironment, with immunological cells playing a central role in efficiency of HER2-targeted antibodies. Here we investigated the prognostic significance of different metastatic sites and their correlation to tumour immune profiles in HER2-positive breast cancer treated with trastuzumab.

Methods

We collected all (n = 54) HER2-positive metastatic breast cancer patients treated with trastuzumab containing regimens at Oulu University Hospital 2009-2014. Pathological and clinical data were collected from electronic patient records. T

SUBMITTER: Honkanen TJ 

PROVIDER: S-EPMC8763933 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature